One-glance verdict
Undervalued
$27.63 our estimate vs market $12.13
Wall Street consensus: $19.75 (-28.5% lower than our fair-value estimate)
56% below our estimate, below the bear case
Fundamentals snapshot
AngioDynamics, Inc.
ANGO · NMS · Healthcare · Medical Instruments & Supplies
Current price
$12.13
52-week range
$9.39 - $16.29
Market cap
$510.12M
Balance sheet
Healthy
-8.26x Concerning
Net cash $23.23M. Interest coverage shows how many times profit covers the interest bill.
What stands out
2 Rewards
2 Risks
2 rewards · 2 risks
- Reward Revenue grew 1.6% last year.
- Reward Free cash flow was positive in 5/10 years.
- Risk Return on equity was -19.2% last year — the company lost money on shareholders' equity.
- Risk Operating margin compressed from -5.5% to -7.8% over 3 years.
What this company does
AngioDynamics, Inc.
AngioDynamics makes medical tools to help doctors treat serious conditions like heart disease and cancer, with their main money coming from selling these devices to hospitals. This matters because their innovative products, like the Auryon system for clearing blockages, can help patients recover more smoothly.
How the company got here
AngioDynamics, Inc. was founded in 1988 and has since become a player in the medical technology field. The company has focused on developing and selling products aimed at treating serious conditions like cardiovascular disease and cancer. Over the years, AngioDynamics has evolved its product offerings to address specific needs within these complex medical areas, building its business through innovation and strategic product development.
What it actually does
AngioDynamics designs, makes, and sells medical devices used by healthcare professionals. These products help doctors diagnose and treat diseases, particularly those affecting blood vessels and organs. Think of them as specialized tools that enable minimally invasive procedures, aiming to improve patient outcomes and recovery times compared to traditional surgery.
Med Tech
This part of AngioDynamics focuses on technologies for treating cardiovascular disease and cancer. For instance, they offer systems like the Auryon Atherectomy system, which helps clear blockages in blood vessels, and the NanoKnife system, an alternative to heat-based methods for destroying cancerous tissue. These products are crucial for interventional cardiologists and oncologists, representing a significant portion of the company's business.
Med Device
The Med Device segment encompasses a broader range of products used in various medical procedures. This includes devices for managing blood clots, such as the AlphaVac mechanical thrombectomy system, and specialized catheters for delivering medication or draining fluids. They also provide equipment for endovascular laser treatments to address vein issues and microwave ablation systems for tissue treatment, contributing to the company's overall revenue stream.
What management is betting on now
AngioDynamics is likely focusing on expanding its portfolio of innovative medical technologies, particularly in areas with high unmet needs like complex cardiovascular interventions and cancer ablation. The company's strategy probably involves continued investment in research and development to bring new devices to market and enhance existing ones. They aim to provide physicians with advanced tools that offer better patient results and streamline procedures, thereby growing their market share in the competitive medical device industry.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2025 Q2
$1.68M
FY2025 Q3
$-14.96M
FY2025 Q4
$18.03M
FY2026 Q1
$-16.64M
FY2026 Q2
$4.24M
FY2026 Q3
$-4.12M
FY2026 Q4
$17.04M
FY2027 Q1
$-15.71M
Revenue
$80.92M
Net income
$-7.10M
Diluted EPS
-0.17
Operating cash flow
$-15.33M
Free cash flow
$-15.71M
Fetching…
Sources
Revenue
$86.61M
Net income
$-11.40M
Diluted EPS
-0.28
Operating cash flow
$17.45M
Free cash flow
$17.04M
Fetching…
Sources
Revenue
$78.42M
Net income
$-8.08M
Diluted EPS
-0.19
Operating cash flow
$-3.11M
Free cash flow
$-4.12M
Fetching…
Sources
Revenue
$79.43M
Net income
$-6.35M
Diluted EPS
-0.15
Operating cash flow
$4.66M
Free cash flow
$4.24M
Fetching…
Sources
Revenue
$75.71M
Net income
$-10.90M
Diluted EPS
-0.26
Operating cash flow
$-15.91M
Free cash flow
$-16.64M
Fetching…
Sources
Revenue
$80.16M
Net income
$-6.05M
Diluted EPS
-0.15
Operating cash flow
$18.81M
Free cash flow
$18.03M
Fetching…
Sources
Revenue
$72.00M
Net income
$-4.41M
Diluted EPS
-0.11
Operating cash flow
$-13.16M
Free cash flow
$-14.96M
Fetching…
Sources
Revenue
$72.84M
Net income
$-10.74M
Diluted EPS
-0.26
Operating cash flow
$2.47M
Free cash flow
$1.68M
Fetching…
Sources
Is it cheap or expensive?
Fair value $27.63 vs current price $12.13
Wall Street consensus is the average analyst price target: $19.75 (-28.5% lower than our fair-value estimate).
Our most-likely fair value is $27.63 a share — about 127.8% above today's price of $12.13, so the stock currently looks cheap (undervalued).
Is it drowning in debt?
Healthy
Net cash $23.2M - more cash than debt. Interest coverage -8.3x.
Net debt
$-23.23M
Interest coverage
-8.26x
AngioDynamics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ANGO
BASELINE
AngioDynamics, Inc.
Total debt $10.74M Interest coverage -8.26x This is the baseline the peer rows are being compared against.
Total debt $2.46M Interest coverage 0.46x This peer still has a real interest-payment cushion, while ANGO does not.
Total debt $190.25M Interest coverage 13.10x This peer still has a real interest-payment cushion, while ANGO does not.
Total debt $17.21M Interest coverage 63.51x This peer still has a real interest-payment cushion, while ANGO does not.
Total debt $111.18M Interest coverage -11.96x Neither company has much profit cushion over interest right now.
Total debt $74.22M Interest coverage -1.61x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ANGO
2 Rewards
2 Risks
Rewards
-
Revenue grew 1.6% last year.
-
Free cash flow was positive in 5/10 years.
Risks
-
Return on equity was -19.2% last year — the company lost money on shareholders' equity.
-
Operating margin compressed from -5.5% to -7.8% over 3 years.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-107.03x
P/B
3.14x
P/S
1.57x
EV/EBITDA
374.98x
PEG ratio
1.41x
Profitability
How much profit each dollar creates
Gross margin
55.3%
Operating margin
-7.8%
Net margin
-10.1%
ROE
-19.2%
ROA
-5.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.07x
Current ratio
2.40x
Quick ratio
1.32x
Total debt
$10.74M
Total cash
$33.97M
Growth
How the business has been compounding
Revenue TTM
$325.38M
Revenue 5Y CAGR
0.3%
EPS TTM
-0.78
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$3.67M
Free CF TTM
$508.00K
FCF margin
0.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—